Synthesis and characterization of new porphyrazine-Gd(III) conjugates as multimodal MR contrast agents
about
Lanthanide probes for bioresponsive imagingMacromolecular Imaging Agents Containing Lanthanides: Can Conceptual Promise Lead to Clinical Potential?Ln[DO3A-N-α-(pyrenebutanamido)propionate] complexes: optimized relaxivity and NIR optical properties.Design of a Gd-DOTA-phthalocyanine conjugate combining MRI contrast imaging and photosensitization properties as a potential molecular theranostic.Redox-triggered self-assembly of gadolinium-based MRI probes for sensing reducing environmentFunctionalisation of lanthanide complexes via microwave-enhanced Cu(I)-catalysed azide-alkyne cycloaddition.Synthesis and characterization of a porphyrazine-Gd(III) MRI contrast agent and in vivo imaging of a breast cancer xenograft model.The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging.Concerning correct and incorrect assignments of Soret (S2-S0) fluorescence in porphyrinoids: a short critical review.Mechanistics and photo-energetics of macrocycles and photodynamic therapy: An overview of aspects to consider for research.Gadolinium-encapsulating iron oxide nanoprobe as activatable NMR/MRI contrast agent.Neutral glycoconjugated amide-based calix[4]arenes: complexation of alkali metal cations in water.Concerning the dual emission of porphyrazines employed in biomedical imaging.Discovery of the Antitumor Effects of a Porphyrazine Diol (Pz 285) in MDA-MB-231 Breast Tumor Xenograft Models in Mice.A new metallostar complex based on an aluminum(III) 8-hydroxyquinoline core as a potential bimodal contrast agent.A self-assembled complex with a titanium(IV) catecholate core as a potential bimodal contrast agent.
P2860
Q27000361-7EAD8657-2CFB-413A-93AE-8E1BDF3BA5C4Q30596925-39522C71-09BF-4846-858E-E8D7B07222C2Q30716845-B1BEA304-4343-4A5A-A0BF-5CD868330E40Q30843294-074428B7-0BD6-4919-BF15-F58B5845EBE8Q34074857-0B06A613-A663-4271-BCAF-0597DFF322F7Q34278539-562F64AF-6FF7-4801-9894-C7E93E661BD5Q35082611-A3C5D913-DB66-4F7F-9770-179A16C076C6Q38080002-7A598395-CF0D-4F7F-A659-32FDBD766708Q38213542-114F058D-C180-4658-A035-0FE10CB4FABFQ39138277-2EE98B36-34C5-4594-A53F-9E9A24BF83B3Q39312451-A05D6300-2829-47C3-8921-344FD0889155Q47728048-8919C50C-E78B-405C-8E58-BE0AC424C1F5Q50235538-B03027CC-3C2D-4BBE-B721-0B902B7B342BQ50431829-30F00DB0-F572-48C7-8312-4C87BDE3BA8AQ50493093-46F5E805-DA43-4FCB-B031-7001BCB0124CQ50506620-3F876429-906C-4EC0-A7F3-D608EE96F57C
P2860
Synthesis and characterization of new porphyrazine-Gd(III) conjugates as multimodal MR contrast agents
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Synthesis and characterization of new porphyrazine-Gd
@nl
Synthesis and characterization ...... multimodal MR contrast agents
@ast
Synthesis and characterization ...... multimodal MR contrast agents
@en
type
label
Synthesis and characterization of new porphyrazine-Gd
@nl
Synthesis and characterization ...... multimodal MR contrast agents
@ast
Synthesis and characterization ...... multimodal MR contrast agents
@en
prefLabel
Synthesis and characterization of new porphyrazine-Gd
@nl
Synthesis and characterization ...... multimodal MR contrast agents
@ast
Synthesis and characterization ...... multimodal MR contrast agents
@en
P2093
P2860
P356
P1476
Synthesis and characterization ...... multimodal MR contrast agents
@en
P2093
Anthony G M Barrett
Benjamin J Vesper
Brian M Hoffman
Evan R Trivedi
James A Radosevich
Thomas J Meade
P2860
P304
P356
10.1021/BC1002828
P577
2010-11-09T00:00:00Z